Biotech and Pharmaceuticals Pharmaceuticals

More

  • Stocks to Watch: July 29, 2016

    Merck, Exxon Mobil and Amazon are making headlines this Friday morning before the opening bell.

  • Drugmaker Merck& Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for cancer and Zepatier for hepatitis C, still posted a big jump in second-quarter profit thanks to slightly higher sales and more cost cutting. The drugmaker is transitioning to a hoped-for new growth cycle fueled by those recently launched,...

  • PARIS— Drugmaker Sanofi has reported an 11 percent fall in profit in the second quarter despite double-digit growth of its biotech unit Genzyme. Genzyme was Sanofi's strongest performer with sales growth of 20.1 percent, due mainly to its multiple sclerosis and rare disease franchises, followed by its animal health divisions, where sales were up 9.1 percent.

  • DNA Sequencing film strip.

    Intellia Therapeutics is hoping to transform the future of medicine with its gene-editing technology.

  • NEW YORK, July 28- Biotech returned to the good graces of investors this month and it may be the beginning of a revival for stocks in the industry. "I am hearing from a lot of investors who were previously bearish or not involved that maybe now is the time to jump in," said Chris Raymond, an analyst with Raymond James. "Based on my conversations with a lot of portfolio...

  • NEW YORK, July 28- Biotech returned to the good graces of investors this month and it may be the beginning of a revival for stocks in the industry. "I am hearing from a lot of investors who were previously bearish or not involved that maybe now is the time to jump in," said Chris Raymond, an analyst with Raymond James. "Based on my conversations with a lot of portfolio...

  • Pharma earnings roundup

    CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.

  • Access to insurance: LLY CEO

    John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO, dicusses the need to make changes around the Affordable Care Act.

  • Leadership change at Eli Lilly

    John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO talk about Eli Lilly's succession plan as the company launches a new chapter in its history.

  • LONDON, July 28- Generic competition to cholesterol buster Crestor in the U.S. market pushed second-quarter core earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes. Quarterly core earnings per share, which exclude some items, fell 31 percent to 83 cents as revenue slid 11 percent to $5.60...

  • "Futures pricing indicates a 26 percent chance for a September rate hike and 45 percent for sometime this year," Equlior Securities in Budapest said in a note. Earnings season is also under way, begun in Budapest by drug maker Richter reporting a better-than-expected net profit for the second quarter. The bull market continues, a trader said in Budapest.

  • LONDON— Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 percent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States. Core operating profit, which excludes one-time items such as restructuring costs and impairments, dropped to $1.41 billion...

  • July 27- Buyout firms Advent International and CVC Capital Partners have made offers to acquire inVentiv Group Holdings, a pharmaceutical research firm seeking to go public at a valuation of over $4 billion including debt, people familiar with the matter said. Thomas H. Lee Partners, the private equity firm that owns inVentiv, will decide by next week whether to...

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. "Millions of Americans rely daily on generic drugs to treat a wide range of illnesses," Debbie Feinstein, director of the FTC's...

  • NEW YORK— Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal. The FTC said Allergan runs the third-largest generics company in the U.S. That business previously belonged...

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest more than 75 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. The $40.5 billion deal, which was announced in July 2015, solidifies Teva's position as the world's No. 1 maker of...

  • July 27- Eli Lilly& Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday. Company veteran David Ricks will become CEO on Jan. 1, after John Lechleiter, 62, retires by year-end, the Indianapolis- based drugmaker said.

  • WASHINGTON, July 27- Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest more than 75 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

  • MRI image of brain showing area of Alzheimer patient.

    TauRx's drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer's, a study showed.

  • *Government says decision a clear vote of confidence in UK. LONDON, July 27- GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. GSK is investing in sites at Barnard Castle, in the north of England, Montrose, in...